Insilico Medicine Partners with Qilu Pharma on AI Drug Development
Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...
Insilico Medicine (HKG: 3696), a China‑based generative AI‑driven biotech, announced a strategic partnership with Qilu...
Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology...
Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA...
Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...
Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical...
InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering...
Insilico Medicine and TaiGen Biotechnology (including its Beijing subsidiary TaiGen Biopharmaceuticals) announced an exclusive pipeline...
Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...
Insilico Medicine, a global leader in generative AI‑driven drug discovery, announced a strategic partnership with...
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...
China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted...
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in...
China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...
Chengdu-based, generative artificial intelligence (AI)-driven clinical stage biotech company, Insilico Medicine, has announced the receipt...
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...